Risk of incident claims for chemotherapy ‐induced peripheral neuropathy among women with breast cancer in a Medicare population

CONCLUSIONSThese Medicare claims database findings indicate that women aged 66 years or older with breast cancer are susceptible to CIPN from taxane and/or platinum compounds, with risk emerging approximately 3 months into treatment. Prospective studies of symptom emergence and clinical response (eg, stopping chemotherapy and adjunctive treatments) are indicated to determine how best to inform patients of this risk and to manage CIPN in this population.

Source: Cancer - November 2, 2018 Category: Cancer & Oncology Authors: Mark K. Greenwald, Julie J. Ruterbusch, Jennifer L. Beebe ‐Dimmer, Michael S. Simon, Terrance L. Albrecht, Ann G. Schwartz Tags: Original Article Source Type: research